AnalystBook Research · Company Intelligence

Grace Therapeutics, Inc.

GRCENasdaq

Built from Grace Therapeutics, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data

Net loss narrowed 25.6% to $9.6M, while Operating cash flow decreased 20.8% to −$14.9M.

The read at a glance✓ Audited against SEC data
  • Scale — FY2025 revenue N/AWatch
  • Profitability — Net loss $9.6MWatch
  • Cash generation — Free cash flow −$14.9MNote
  • Insiders — 0 buys; 0 sells in 365 daysNote
  • Capital — Comparable payout data unavailableNote

Business

Grace Therapeutics, Inc.: We may not be able to maintain our operations and advance our research and development and commercialization of our GTx-104 lead drug candidate without additional funding.

Latest filings

  • 8-K · Company announcement2026-09-18
  • 8-K · Company announcement2026-08-13
  • 10-Q · Quarterly report2026-08-13
  • 8-K · Company announcement2026-08-06
  • 8-K · Company announcement2026-07-28
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Grace Therapeutics, Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

See the full GRCE record — start free

14-day free trial, no credit card. For research purposes only; not investment advice.